A systems approach to enhance clinical research and medicines development

Authors

    Honorio Silva, Greg Koski, Matthew Whalen, Mary Tobin, Beat Widler, Al O. Pacino II, Brian Edwards

DOI:

https://doi.org/10.18063/jmds.v1i1.111

Keywords:

clinical research, systems approach, site accreditation, core competencies, shared information technology platform

Abstract

The biopharmaceutical industry has traditionally been the key link between basic biomedical discovery and novel medicines. Today, the industry faces numerous challenges including the broad agreement that the current clinical trial system is inefficient and flawed. Most challenges are worsened by the inability of the stakeholders to work collaboratively. Over the last decade, many cooperative efforts to transform clinical research have been launched, but a systemic solution has not been envisioned. A systems approach, including the application of systems engineering principles, has been used in other sectors and proposed for use in healthcare and medicines development. Clinical research, when looked at in systems terms, can be defined as an open system involving patients, investigators and associated staff, regulators, sponsors and stakeholders interconnected through a series of processes to bring effective and safe medicines into the market. ACRES is a global nonprofit organization with a mission of creating a multi-sector alliance of individuals and institutions collaborating on building a shared global system for clinical research excellence. A fundamental element of the ACRES system includes a global network of high-performing research sites interconnected through a shared information technology platform, with standardized policies and operational procedures and a robust, secure database to support performance, quality and safety. Five core initiatives address the larger mission and are currently ongoing. Deliverables will roll out over 2015–2018. Positive reception to the concept, vision and goals among critical stakeholders, and a steady influx of strategic allies willing to work collaboratively demonstrates the strong pull exerted by the vision of a global system. However, due to the undertakings’ scope and complexity, challenges remain. Recognition that effective shared collaboration is the best long-term option among stakeholders and the general public constitutes a powerful incentive for ACRES contributors and strategic allies to keep working and make it happen.

References

Honig P and Huang S-M, 2014, Intelligent pharmaceuti-cals: beyond the tipping point. Clinical Pharmacology & Therapeutics, vol.95(5): 455–459.

http://dx.doi.org/10.1038/clpt.2014.32.

Misik V, Brady R V, Bolecek M, et al. 2014, Current trends in globalization of industry-sponsored clinical tri-als. Applied Clinical Research, Clinical Trials and Regu-latory Affairs, vol.1: 56–66.

http://dx.doi.org/10.2174/2213476X01666131111191016.

Lang T and Siribaddana S, 2012, Clinical trials have gone global: is this a good thing? PLoS Medicine, vol.9(6): e1001228.

http://dx.doi.org/10.1371/journal.pmed.1001228.

Paul S M, Mytelka D S, Dunwiddie C T, et al. 2010, How to improve R&D productivity: the pharmaceutical indus-try’s grand challenge. Nature Reviews Drug Discovery, vol.9(3): 203–214.

http://dx.doi.org/10.1038/nrd3078.

Munos B H, 2014, Accelerating innovation in the bios-cience revolution, in Collaborative Innovation in Drug Discovery, John Wiley & Sons, Inc., Hoboken, 195–212.

http://dx.doi.org/10.1002/9781118778166.ch13.

Executive Office of the President 2012, PCAST report on propelling innovation in drug discovery, development and evaluation, viewed May 1, 2015,

IOM (Institute of Medicine), 2012, Envisioning a Trans-formed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020: Workshop Summary. The National Academies Press, Washington DC.

Karlberg J P E, 2009, US FDA site inspection findings, 1997–2008, fail to justify globalization concerns. Clinical Trials Magnifier, vol.2(5): 194–212.

Khin N A, Yang P, Hung H M J, et al. 2013, Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the united states: an FDA perspective. Clinical Pharmacology & Therapeutics, vol.94(2): 230–242.

http://dx.doi.org/10.1038/clpt.2013.70.

Silva H, Kesselring G F, Yrivarren J L, et al. 2014, Edu-cation and training needs among clinical investigators and medicines development professionals from two Latin American countries. Clinical Researcher, vol.28: 18–25.

Sonstein S A, Seltzer J, Li R, et al. 2014, Moving From Compliance to Competency: A Harmonized Core Com-petency Framework for the Clinical Research Profession-al. Clinical Researcher, vol.28(3): 17–23.

Boeynaems J-M, Canivet C, Chan A, et al. 2013, A Eu-ropean approach to clinical investigator training. Fron-tiers in Pharmacology, vol.4: 112.

http://dx.doi.org/10.3389/fphar.2013.00112.

Speicher L A, Fromell G, Avery S, et al. 2012, The critical need for academic health centers to assess the training, support, and career development requirements of clinical research coordinators: recommendations from the clinical and translational science award research coordinator taskforce. Clinical and Translational Science, vol.5(6): 470–475.

http://dx.doi.org/10.1111/j.1752-8062.2012.00423.x.

Sahoo U, 2012, Clinical Research in Asia: Opportunities and Challenges, Woodhead Publishing. Cambridge UK, viewed May 1, 2015,

Clinical Trials Transformation Initiative n.d., viewed May 1, 2015,

The Innovative Medicines Initiative n.d., viewed May 1, 2015,

The Multi Regional Clinical Trials Center at Harvard University n.d., viewed May 1, 2015,

CDISC n.d., viewed May 1, 2015,

TransCelerate n.d., viewed May 1, 2015,

Better Health Care and Lower Costs: Accelerating Im-provement through Systems Engineering, 2014, Report to the USA President. President’s Council of Advisors on Science and Technology, viewed May 1, 2015,

Helikar T, Kowal B and Rogers J A, 2013, A cell simula-tor platform: the cell collective. Clinical Pharmacology & Therapeutics, vol.93(5): 393–395.

http://dx.doi.org/10.1038/clpt.2013.41.

Vicini P and van der Graaf P H, 2013, Systems pharma-cology for drug discovery and development: paradigm shift or flash in the pan? Clinical Pharmacology & The-rapeutics, vol.93(5): 379–381.

http://dx.doi.org/10.1038/clpt.2013.40.

Wikipedia. Systems and Systems Theory, viewed May 1, 2015,

Meadows D H, 2008, Thinking in systems: A Primer. Chelsea Green Publishing, River Junction. VT

Alsumidale M, TransCelerate vs. ACRES: Site Accreditation Initiatives. Applied Clinical Trials, viewed May 1, 2015,

Downloads

Published

2016-07-21